Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions

Paula Robinson; David Anderson; Melissa Brouwers; Thomas E Feasby; Heather Hume; IVIG Hematology and Neurology Expert Panels

doi:10.1016/j.tmrv.2007.01.004

Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions

Transfus Med Rev. 2007 Apr;21(2 Suppl 1):S3-8. doi: 10.1016/j.tmrv.2007.01.004.

Authors

Paula Robinson¹, David Anderson, Melissa Brouwers, Thomas E Feasby, Heather Hume; IVIG Hematology and Neurology Expert Panels

Affiliation

¹ Transfusion Medicine, Canadian Blood Services, Ottawa, ON, Canada.

PMID: 17397767
DOI: 10.1016/j.tmrv.2007.01.004

Abstract

In Canada, intravenous immune globulin (IVIG) use has increased by 115% over the past 7 to 8 years. Given this increased usage, Canadian Blood Services and the National Advisory Committee on Blood and Blood Products for Canada identified the need to develop and disseminate evidence-based guidelines to facilitate appropriate IVIG use. As a result, guidelines for IVIG use in hematologic and neurologic conditions have been developed and are published in this supplement of Transfusion Medicine Reviews. This commentary provides a brief description of the process used to develop these guidelines and includes a summary of the recommendations for IVIG use in the various conditions evaluated.

Publication types

Practice Guideline

MeSH terms

Blood Banks
Canada
Drug Utilization
Evidence-Based Medicine*
Hematologic Diseases / drug therapy*
Humans
Immunoglobulins, Intravenous / therapeutic use*
Nervous System Diseases / drug therapy*
Practice Guidelines as Topic*

Substances

Immunoglobulins, Intravenous